Company

ProteoMediX AG is a spinoff company of ETH Zurich located on the Science City campus at the Hönggerberg site. In 2010, the company was co-founded by Dr. Ralph Schiess, Christian Brühlmann, Prof. Dr. med. Thomas Cerny, Prof. Dr. Wilhelm Krek and Prof. Dr. Ruedi Aebersold. The technology and the first product for prostate cancer was developed by a multidisciplinary group of basic scientist and clinicians, a prerequisite for success.